• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks
    medical device investing

    Atrion Reports 2017 Results for Fourth Quarter and Full Year

    Gabrielle Lakusta
    Feb. 28, 2018 09:18AM PST
    Medical Device Investing

    Atrion (NASDAQ:ATRI) announced today that for the fourth quarter of 2017 revenues were $34.0 million compared to $33.3 million in the same period of 2016, net income was $8.6 million compared to $5.6 million, and diluted earnings per share were $4.66 compared to $3.00 in the prior-year period. As quoted in the press release: David …

    Atrion (NASDAQ:ATRI) announced today that for the fourth quarter of 2017 revenues were $34.0 million compared to $33.3 million in the same period of 2016, net income was $8.6 million compared to $5.6 million, and diluted earnings per share were $4.66 compared to $3.00 in the prior-year period.

    As quoted in the press release:

    David Battat, President & CEO, commenting on the results for the fourth quarter and the full year 2017 as compared to the prior-year periods said, “We had a solid fourth quarter with revenues up 2% and operating income up 9%. Full-year revenues were up 2%, and more importantly operating income was up 5%. I am especially pleased that growth in our fluid delivery and cardiovascular products more than made up for ongoing customer issues adversely impacting ophthalmic sales. GAAP net income and diluted EPS were both up 55% in the 2017 fourth quarter, and up 33% for the full year.”

    Click here to read the full press release.

    medical device investing
    The Conversation (0)

    Go Deeper

    AI Powered
    Bristol Myers Squibb Reports First Quarter Financial Results for 2023

    Bristol Myers Squibb Reports First Quarter Financial Results for 2023

    Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Medical Device Investing Stocks

    Cardiex Limited

    CDX:AU

    Cleo Diagnostics

    COV:AU

    Ocumetics Technology

    OTC:CA

    Premier Health of America

    PHA:CA

    Bloom Health Partners

    BLMH:CNX

    Applied UV

    AUVI:NSD
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×